AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01358175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02627534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic debridement
Description: All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
Study NCT02627534 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic debridement
Description: All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
Study NCT02627534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy
Description: After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
Study NCT02551003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous cord blood
Description: Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
Study NCT02551003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia
Description: Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
Study NCT03065283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm lift
Description: The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice
Study NCT02586961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline solution
Description: Placebo:~Nebulized 0.9% saline solution
Study NCT02586961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral betamethasone placebo
Description: placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
Study NCT02586961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline
Description: Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)
Study NCT02586961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral betamethasone
Description: Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
Study NCT03065283 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Diaphragm lift
Description: The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice
Study NCT03065283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation of the diaphragm pillars
Description: Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute
Study NCT03065283 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Relaxation of the diaphragm pillars
Description: Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute
Study NCT04699643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVER4010001
Description: Please refer to information in arm/group descriptions.
Study NCT00798785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-MMF-TAC
Description: ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver.
Study NCT00798785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-Rituximab-MMF-TAC
Description: ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver.
Study NCT00798785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-basilixumab-MMF-TAC
Description: First transplantation:~ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Second transplantation:~Basilixumab:~the day before the second transplantation followed by 4days after transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver.
Study NCT00798785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: omentum
Description: Two clinical implants: first in omentum followed by a clinical implant in the liver:~In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels >= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum.
Study NCT02971865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT/CMT
Description: Cognitive Behavioral Therapy (CBT - training to change nutritional thoughts and behaviors) and Chiropractic Manipulative Therapy (CMT - High Velocity, low amplitude chiropractic manipulation) were delivered in average total 8 visits in a year. The interventions were comparable in format (individual visit), duration (30 minute visits), frequency (monthly), and number of participants per group (see intervention details). Each intervention was delivered according to a protocol in which all instructors were trained. (Figure 3: Chiropractic/Behavioral health and Primary care Integration Protocol.) Routine care varied with patient complaints at the time of visit.
Study NCT03841227 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-tDCS
Description: Active home-based tDCS applied at home. 5 days a week for 4 weeks.
Study NCT02971865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group traditional primary care
Description: No change in care usually given
Study NCT02028702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water with color
Study NCT02028702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red Clover extract
Description: Red Clover extract containing 80 mg Isoflavones. Dosage: 2 X 75 ml/day
Study NCT02581761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYTOTEC
Description: synthetic prostaglandin E1
Study NCT02581761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active material
Study NCT01503359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sarcosine
Description: Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months.
Study NCT01503359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sarcosine
Description: Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months.
Study NCT02170129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 50% AAB plus 50% autologous bone
Description: All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later.~Both groups received tapered implants with an anodised surface.
Study NCT02170129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 100% AAB
Description: All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later. Both groups received tapered implants with an anodised surface.
Study NCT04036383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular exercise training
Description: The home exercise program consists of vestibulookular reflex stimulating exercises, lower extremity somatosensory system training, static and dynamic balance exercises
Study NCT04036383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vestibular exercise training
Description: The home exercise program consists of vestibulookular reflex stimulating exercises, lower extremity somatosensory system training, static and dynamic balance exercises
Study NCT04036383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training with computerized balance system
Description: Thanks to the receivers under the Neurocom balance master platform, the data of the center of gravity is transferred to the system and visual feedback is provided. Qualitative information reflects progression during static and dynamic postural exercises of the patient. To correct the load distribution, it is necessary to move the cursor to the specified targets in the exercises. The degree of difficulty of training can be increased by increasing the distance between the targets, reducing the time required to reach the targets, changing foot positions or adding upper extremity activity.
Study NCT04036383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance training with computerized balance system
Description: Thanks to the receivers under the Neurocom balance master platform, the data of the center of gravity is transferred to the system and visual feedback is provided. Qualitative information reflects progression during static and dynamic postural exercises of the patient. To correct the load distribution, it is necessary to move the cursor to the specified targets in the exercises. The degree of difficulty of training can be increased by increasing the distance between the targets, reducing the time required to reach the targets, changing foot positions or adding upper extremity activity.
Study NCT04036383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: square step exercises
Description: Elderly individuals in the square step exercise group will perform step exercises on 2.5x1.0 m thin cushions divided into 40 equal parts. Square step exercises include exercises that include anterior, posterior, lateral and diagonal directions of increasing difficulty. The order of the training program is at four different levels and is organized according to small, basic, regular and advanced levels.
Study NCT04036383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: square step exercises
Description: Elderly individuals in the square step exercise group will perform step exercises on 2.5x1.0 m thin cushions divided into 40 equal parts. Square step exercises include exercises that include anterior, posterior, lateral and diagonal directions of increasing difficulty. The order of the training program is at four different levels and is organized according to small, basic, regular and advanced levels.
Study NCT02836340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Iminobiotin
Description: The Investigational Medicinal Product (IMP) under study is 2-IB, which is a biotin (Vitamin H or B7) analogue and a selective inhibitor of neuronal and inducible nitric oxide synthase (NOS).
Study NCT02680977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MP-Equivalent
Description: Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.
Study NCT02680977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MP-Low
Description: Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI
Study NCT02680977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MP+DDCI
Description: Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.
Study NCT02680977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LD+DDCI
Description: Levodopa plus Benserazide
Study NCT02680977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LD-DDCI
Description: Levodopa without any DDCI
Study NCT02680977 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Groundnuts powder
Study NCT04613895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
Study NCT04613895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
Study NCT04551352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7293583
Description: RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.
Study NCT04551352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).
Study NCT04551352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: If implemented, it will be given either on D-7 or D-7 and D-6.
Study NCT04551352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: If implemented, it will be given as a single dose approximately 6 days prior to the first dose of RO7293583.
Study NCT02196506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + ADT
Description: Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
Study NCT01950468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAV5001
Description: A single intravenous dose of 8.0 ± 1.0 mCi
Study NCT01950468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DaTscan
Description: A single intravenous dose of 3 to 5 mCi
Study NCT00984542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
Study NCT03105362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enterade® oral rehydration solution
Description: Commercially available amino acid based oral rehydration solution
Study NCT02196506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole +ADT
Description: Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
Study NCT00846196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate DR (Phase III clinical supply)
Description: Reference - (Phase III clinical supply) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
Study NCT00846196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate 35 mg DR (Commercial Tablet)
Description: Test - (Commercial tablets) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
Study NCT03816800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ImmunoBon
Description: The dietary agent contains vitamin A, Zn, chelated iron and whey proteins.
Study NCT03816800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the dietary agent does not contain vitamin A, Zn, chelated iron and whey proteins
Study NCT04130945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block, cost analysis
Description: in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation
Study NCT04036448 — intervention group
Intervention type: DRUG
Intervention: REVLIMID®
Description: REVLIMID®
Study NCT01925430 — intervention group
Intervention type: DEVICE
Intervention: Screening device
Description: Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.
Study NCT01925430 — intervention group
Intervention type: DEVICE
Intervention: Comparative product
Description: A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
Study NCT03152877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome Injectable Product
Description: 20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
Study NCT03152877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% plain bupivacaine
Description: 20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
Study NCT01616797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized neurobehavioral intervention
Description: Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
Study NCT01616797 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computerized neurobehavioral intervention
Description: Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
Study NCT00913263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-hydroxyflutamide (2-HOF) [Liproca Depot]
Description: Ready made paste including 600 mg 2-HOF for injection as a single dose
Study NCT00913263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Hydroxyflutamide
Description: The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to administration.
Study NCT00313196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg
Study NCT02790099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.
Study NCT02790099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.